Clinical significance of MART-1 and HLA-A2 expression and CD8+ T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients.
J Dermatol Sci, 2001/1;25(1):36-44.
Kageshita T[1], Kawakami Y, Ono T
Affiliations
PMID: 11154862
Impact factor: 5.408
Abstract
MART-1 is a good candidate antigen for immunotherapy against HLA-A2 patients with melanoma, since it is a highly immunogenic antigen recognized by HLA-A2 and HLA-B45 restricted CD8+ cytotoxic T cells and expressed in the majority of melanoma lesions. In the present study the expression of MART-1 and HLA-A2 on melanocytic cells and CD8+ T cell infiltration was immunohistochemically analyzed. MART-1 was expressed in most melanocytic lesions, while HLA-A2 was down-regulated with melanoma disease progression. Furthermore, concomitant down-regulation of MART-1 and HLA-A2 in melanoma cells was correlated with poor prognosis. These findings suggest both MART-1 and HLA-A2 expression in melanoma lesions should be analyzed for selection of patients eligible for MART-1 based immunotherapy and monitoring for emergence of melanoma cells resistant to T cell therapy.
MeSH terms
Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Child; Female; HLA-A2 Antigen; Histocompatibility Antigens Class I; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; MART-1 Antigen; Male; Melanocytes; Melanoma; Middle Aged; Neoplasm Proteins; Skin Diseases; Skin Neoplasms; Staining and Labeling
More resources
EndNote: Download